These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1450 related items for PubMed ID: 25619164

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G, Tentori L, Navarra P.
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [Abstract] [Full Text] [Related]

  • 5. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [Abstract] [Full Text] [Related]

  • 6. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E, Kwong BY, Swetter SM, Pugliese SB.
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [Abstract] [Full Text] [Related]

  • 7. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.
    Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R.
    Cancer Treat Rev; 2017 Jun; 57():36-49. PubMed ID: 28550712
    [Abstract] [Full Text] [Related]

  • 8. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA, Hodi FS, Robert C.
    Clin Cancer Res; 2013 Oct 01; 19(19):5300-9. PubMed ID: 24089443
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM, Margolin K.
    Semin Oncol; 2015 Jun 01; 42(3):459-65. PubMed ID: 25965364
    [Abstract] [Full Text] [Related]

  • 14. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
    Michielin O, Hoeller C.
    Cancer Treat Rev; 2015 Sep 01; 41(8):660-70. PubMed ID: 26096079
    [Abstract] [Full Text] [Related]

  • 15. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A, Larkin J.
    Expert Opin Drug Saf; 2017 Aug 01; 16(8):955-961. PubMed ID: 28679287
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.